【摘要】 目的探讨β1肾上腺素受体(β1-Adrenergic Receptor,ADRB1)Arg389Gly基因多态性与ADRB1阻滞剂降压疗效的相关性。方法采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)分析412例原发性高血压患者ADRB1Arg389Gly基因多态性,将患者分成Arg389Arg组,Arg389Gly组和Gly389Gly组,观察比索洛尔治疗8周后血压变化的组间差异。结果比索洛尔治疗8周后,Arg389Arg组,Arg389Gly组和Gly389Gly组收缩压(SBP)分别下降了12.1%±4.5%,3.4%±4.1%和1.3%±1.0%,舒张压(DBP)分别下降了6.9%±4.4%,2.5%±4.1%和0.8%±4.0%,修改为收缩压(SBP)分别下降了(12.1±4.5)mmHg,(3.4±4.1)mmHg和(1.3±1.0)mmHg,舒张压(DBP)分别下降了(6.9±4.4)mmHg,(2.5±4.1)mmHg和(0.8±4.0)mmHg。组间比较差异均有统计学意义(均P<0.01)。结论ADRB1的Gly389Arg基因多态性与比索洛尔降压疗效相关。更多还原

【Abstract】 Objective To investigate that β1-adrenergic receptor polymorphisms affect the blood pressure response to β-adrenoceptor blockade (bisoprolol) monotherapy in the Chinese population with hypertension.Methods 412 patients with essential hypertension were recruited from outpatient.β1-adrenergic receptor polymorphisms were genotyped by using polymerase chain reaction-restriction fragment length polymorphism.The patients were divided by three groups according to the genotypes,including 201 for Arg389Arg,168 for Arg389Gly,42 for Gly389Gly.All the patients were given bisoprolol every day for 8 weeks.Heart rate and blood pressure were measured weekly during the duration of bisoprolol therapy.Results Systolic blood pressure after bisoprolol administration was significantly different among three groups (12.1%±4.5%,3.4%±4.1% and 1.3%±1.0% for Arg389Arg,Gly389Arg and Gly389Gly,respectively,P<0.01).We also found a similar difference in changes of diastolic blood pressure (6.9%±4.4%,2.5%±4.1% and 0.8%±4.0% respectively,P< 0.01) for Arg389Arg,Gly389Arg and Gly389Gly patients.Conclusion β1-adrenergic receptor polymorphism was associated with different blood pressure responses to bisoprolol therapy in patients with essential hypertension.[HTH]更多还原